Skip to content

Study on Therapeutic Effect Evaluation and Technical Standard of COPD in the Treatment of Yifei Moxibustion

Study on Therapeutic Effect Evaluation and Technical Standard of COPD in the Treatment of Yifei Moxibustion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011194
Enrollment
Unknown
Registered
2017-04-20
Start date
2015-04-01
Completion date
Unknown
Last updated
2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

experimental group:Western standard medical treatment and Yifei Moxibustion
control group:Yifei Moxibustion

Sponsors

The First Affiliated Hospital of Henan traditional Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with COPD in stable period; 2. Aged between 40 and 80 years; 3. Patients with pulmonary qi deficiency,lung and spleen qi deficiency and deficiency of pulmonary and renal qi dialectically; 4. the acute exacerbation at least once last year; 5. No other clinical studies of intervention measures a month before chosen; 6. Be acceptable to Yifei moxibustion therapy; 7. Volunteer to accept treatment and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with Confusion, dementia, all kinds of mental illness; 3. Accompanied by severe cardiac insufficiency; 4. Accompanied by active pulmonary tuberculosis,diffuse panbronchiolitis,pneumothorax, pleural effusion, pulmonary embolism; 5. Accompanied by neuromuscular diseases which influence the breathing movement function; 6. Accompanied by tumor; 7. Severe liver and kidney disease(ALT/AST=3 times normal, Glomerular filtration rate=29); 8. Allergic to known moxibustion powder composition.

Design outcomes

Primary

MeasureTime frame
acute exacerbation of chronic obstructive pulmonary disease;Skin sensitization evaluation;

Secondary

MeasureTime frame
clinical symptoms and signs;modified medical british research council;6minutewalkingdistance;COPDAssessment Test,The MOS 36-Item Short-Form Health Survey;pulmonary function;

Countries

china

Contacts

Public ContactLi Suyun

Henan traditional Chinese Medicine University

lisuyun2000@126.com+86 13938415502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026